212Pb-NG001

N/A

Report date: 2025/11/20 16:00:49
NME

Base Information

Drug Name212Pb-NG001
Drug Alias Name212Pb-p-SCN-Bn-TCMC-PSMA212Pb-NG001AB-001AB001
ClassificationRadiation-emitting products > Nuclides > Lead > 212PbRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive diagnostic agent +[4] 
Mechanisms of ActionAnti-PSMA
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNorway
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesARTBIO Inc
China Registration ClassN/A

Develop Information

Active CompaniesPharmaLogic Holdings CorpShanghai AlphaGen Therapeutics Co LtdSpectronRX +[4] 
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A